88 related articles for article (PubMed ID: 526917)
1. Ocular assessment of patients treated with tamoxifen.
Beck M; Mills PV
Cancer Treat Rep; 1979; 63(11-12):1833-4. PubMed ID: 526917
[TBL] [Abstract][Full Text] [Related]
2. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
[TBL] [Abstract][Full Text] [Related]
3. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use.
Salomão SR; Watanabe SE; Berezovsky A; Motono M
Curr Eye Res; 2007 Apr; 32(4):345-52. PubMed ID: 17453956
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen and ocular toxicity.
Ah-Song R; Sasco AJ
Cancer Detect Prev; 1997; 21(6):522-31. PubMed ID: 9398992
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.
Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL
Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
7. Ocular toxicity in low-dose tamoxifen: a prospective study.
Noureddin BN; Seoud M; Bashshur Z; Salem Z; Shamseddin A; Khalil A
Eye (Lond); 1999 Dec; 13 ( Pt 6)():729-33. PubMed ID: 10707134
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen retinopathy.
Kaiser-Kupfer MI; Lippman ME
Cancer Treat Rep; 1978 Mar; 62(3):315-20. PubMed ID: 647693
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina.
Bradbury BD; Lash TL; Kaye JA; Jick SS
Cancer; 2005 Mar; 103(6):1114-21. PubMed ID: 15712362
[TBL] [Abstract][Full Text] [Related]
10. Stroke risk and tamoxifen therapy for breast cancer.
Geiger AM; Fischberg GM; Chen W; Bernstein L
J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
[TBL] [Abstract][Full Text] [Related]
11. [Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].
Semiglazov VF; Maksimov SIa; Bulgatova EA; Meshkova IE; Chepik OF; Berstein LM
Vopr Onkol; 2003; 49(2):198-204. PubMed ID: 12785205
[TBL] [Abstract][Full Text] [Related]
12. Ocular toxicity of tamoxifen.
Gerner EW
Ann Ophthalmol; 1989 Nov; 21(11):420-3. PubMed ID: 2619152
[TBL] [Abstract][Full Text] [Related]
13. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
14. A clinical assessment of loading dose tamoxifen for advanced breast carcinoma.
Ribeiro GG; Wilkinson PM
Clin Oncol; 1984 Dec; 10(4):363-7. PubMed ID: 6509818
[TBL] [Abstract][Full Text] [Related]
15. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd GT; Adamson PC; Gupta M; Homayoun P; Sandstrom SK; Murphy RF; McLain D; Tuason L; Peereboom D; Bukowski RM; Ganapathi R
Clin Cancer Res; 1998 Mar; 4(3):635-42. PubMed ID: 9533531
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cysts in women receiving tamoxifen for breast cancer.
Mourits MJ; de Vries EG; Willemse PH; ten Hoor KA; Hollema H; Sluiter WJ; de Bruijn HW; van der Zee AG
Br J Cancer; 1999 Apr; 79(11-12):1761-4. PubMed ID: 10206289
[TBL] [Abstract][Full Text] [Related]
19. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
20. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]